Elevation Oncology (NASDAQ:ELEV) vs. Cellectis (NASDAQ:CLLS) Head-To-Head Comparison

Cellectis (NASDAQ:CLLS) and Elevation Oncology (NASDAQ:ELEV) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, institutional ownership, valuation, earnings and dividends.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Cellectis and Elevation Oncology, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cellectis	0	0	2	0	3.00
Elevation Oncology	0	0	5	0	3.00

Cellectis presently has a consensus target price of $8.00, indicating a potential upside of 330.11%. Elevation Oncology has a consensus target price of $7.80, indicating a potential upside of 1,240.21%. Given Elevation Oncology’s higher possible upside, analysts clearly believe Elevation Oncology is more favorable than Cellectis.

Volatility & Risk

Cellectis has a beta of 3.09, meaning that its share price is 209% more volatile than the S&P 500. Comparatively, Elevation Oncology has a beta of 1.22, meaning that its share price is 22% more volatile than the S&P 500.

Insider & Institutional Ownership

63.9% of Cellectis shares are held by institutional investors. Comparatively, 83.7% of Elevation Oncology shares are held by institutional investors. 16.4% of Cellectis shares are held by insiders. Comparatively, 8.1% of Elevation Oncology shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Cellectis and Elevation Oncology’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cellectis	-401.83%	-78.90%	-24.17%
Elevation Oncology	N/A	-57.97%	-38.49%

Valuation & Earnings

This table compares Cellectis and Elevation Oncology”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cellectis	$13.03 million	7.94	-$101.06 million	($1.29)	-1.44
Elevation Oncology	N/A	N/A	-$45.70 million	($0.85)	-0.68

Elevation Oncology has lower revenue, but higher earnings than Cellectis. Cellectis is trading at a lower price-to-earnings ratio than Elevation Oncology, indicating that it is currently the more affordable of the two stocks.

Summary

Elevation Oncology beats Cellectis on 7 of the 11 factors compared between the two stocks.

About Cellectis

Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma. It also develops UCART22 to treat B-cell acute lymphoblastic leukemia; UCARTCS1 and ALLO-605 for the treatment of multiple myeloma; ALLO-316 for renal cell carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART 20×22 for relapsed or refractory B-Cell NHL. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics; and collaboration and license agreement with Cytovia, as well as a collaboration agreement with AstraZeneca to develop novel cell and gene therapy candidate products. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.

About Elevation Oncology

Elevation Oncology, Inc., an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. The company's lead candidate is EO-3021, an antibody-drug conjugate designed to target Claudin 18.2, a clinically validated molecular target. Its EO-3021 selectively delivers a cytotoxic payload directly to cancer cells expressing Claudin 18.2. Elevation Oncology, Inc. has a license agreement with CSPC Megalith Biopharmaceutical Co., Ltd. to develop and commercialize EO-3021. The company was formerly known as 14ner Oncology, Inc. and changed its name to Elevation Oncology, Inc. in February 2020. The company was incorporated in 2019 and is based in Boston, Massachusetts.